Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction: A Randomized Clinical Trial (Empire HF)

Next Previous
Trial Profile

Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction: A Randomized Clinical Trial (Empire HF)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2018

At a glance

  • Drugs Empagliflozin (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms Empire HF

    • Most Recent Events

    • 04 Oct 2018 Planned End Date changed from 1 Jan 2019 to 1 Oct 2019.
    • 04 Oct 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Oct 2019.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top